Based on this model, one would hypothesize that chemotherapeutic treatments that simultaneously target both the androgen and the Perlecan-mediated Sonic Hedgehog pathways would provide the best control of androgen sensitive aggressive prostate cancer. This evidence concerns the gene HSPG2 and prostate carcinoma.